A Possible Link Between HCN Channels and Depression

Chung Sub Kim1 and Daniel Johnston1

Abstract
Growing evidence suggests a possible link between hyperpolarization-activated cyclic nucleotide-gated nonselective cation (HCN) channels and depression. In a recent study published in Molecular Psychiatry, we first demonstrate that Ih (the membrane current mediated by HCN channels) and HCN1 protein expression were increased in dorsal, but not in ventral, CA1 region following chronic, but not acute stress. This upregulation of Ih was restricted to the perisomatic region of CA1 neurons and contributed to a reduction of neuronal excitability. A reduction of HCN1 protein expression in dorsal CA1 region before the onset of chronic unpredictable stress-induced depression was sufficient to provide resilient effects to chronic unpredictable stress. Furthermore, in vivo block of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) pumps, a manipulation known to increase intracellular calcium levels and upregulate Ih, produced anxiogenic-like behavior and an increase in Ih, similar to that observed in chronic unpredictable stress model of depression. Here, we share our view on (1) how the function and expression of HCN1 channels are changed in the brain in a subcellular region-specific manner during the development of depression and (2) how a reduction of HCN1 protein expression provides resilience to chronic stress.

Keywords
hippocampus, HCN1, Ih, chronic unpredictable stress, resilience

Received 6 June 2018; Accepted 19 June 2018


The limbic–cortical system is an integral brain region underlying the action of depression and antidepressants.1,2 Major depression is a mental disorder characterized by an all-encompassing low mood, low self-esteem, and loss of interest or pleasure in enjoyable activities. Current existing antidepressants work mainly on targeting the monoamine system and increasing serotonin levels in the limbic brain areas including hippocampus. The hippocampus is involved in the symptoms of depression such as behavior despair and anhedonia as well as a site of action for antidepressant responses. About 30% of depressed patients do not respond to available antidepressant drugs (i.e., treatment-resistant depression (TRD)).3 This TRD requires trial-and-error combinations of multiple different medication regimens and electrical stimulation therapies.4 Although electrical stimulation therapies (e.g., electro convulsive therapy, deep brain stimulation, and transcranial magnetic stimulation) are often effective to treat TRD through a change in brain activity, they also cause unwanted severe side effects such as memory loss and can be cost prohibitive for patients. Recent groundbreaking clinical findings for TRD demonstrate that a single intravenous injection with a subanesthetic dose of ketamine (0.5 mg/kg over 40 min) provides a rapid and sustained antidepressant effect.5 Given that the U.S. Food and Drug Administration has only approved ketamine, a noncompetitive N-methyl-D-aspartate receptor antagonist, as an anesthetic agent, treatment of depression by ketamine is not covered by treatment-resistant depression drugs (i.e., treatment-resistant depression (TRD)).3 This TRD requires trial-and-error combinations of multiple different medication regimens and electrical stimulation therapies.4 Although electrical stimulation therapies (e.g., electro convulsive therapy, deep brain stimulation, and transcranial magnetic stimulation) are often effective to treat TRD through a change in brain activity, they also cause unwanted severe side effects such as memory loss and can be cost prohibitive for patients. Recent groundbreaking clinical findings for TRD demonstrate that a single intravenous injection with a subanesthetic dose of ketamine (0.5 mg/kg over 40 min) provides a rapid and sustained antidepressant effect.5 Given that the U.S. Food and Drug Administration has only approved ketamine, a noncompetitive N-methyl-D-aspartate receptor antagonist, as an anesthetic agent, treatment of depression by ketamine is not covered by
insurance. Furthermore, ketamine has the potential for side effects such as psychotomimetic effects and drug misuse.

Growing evidence suggests a possible link between hyperpolarization-activated cyclic nucleotide-gated non-selective cation (HCN) channels and depression. Whole-brain knockout mice in which either the pore-forming (HCN1 and HCN2) protein or an auxiliary channel subunit, tetratricopeptide repeat-containing Rab8b interacting protein (TRIP8b) of HCN channels were deleted, all result in a reduction of functional $I_h$ (the membrane current mediated by HCN channels) showed antidepressant-like behaviors. The HCN channels are members of the voltage-gated cation channel superfamily. The HCN1 is a main isoform of HCN channels (HCN1–HCN4) and is highly expressed in the hippocampal CA1 region, showing a gradient of increasing channel expression along the somatodendritic axis. HCN channels are active at the resting membrane potential leading to the generation of a nonactivating inward current that contributes to the intrinsic membrane properties, neuronal excitability, synaptic integration, and synaptic plasticity. Because there is no specific HCN channel blockers or genetic animal models that provide region-specific manipulation of HCN1 channels, we developed a lentiviral shRNA system, which provides sequence-specific manipulation with spatial and temporal control and high transduction efficiency. When HCN1 protein was reduced (about 40%–50%) in dorsal CA1 region (which corresponds to the posterior hippocampus in human) in normal rats, we observed antidepressant- and anxiolytic-like effects in specific behavioral tests (e.g., open-field test, elevated plus maze test, and forced swim test). Given the limited lentiviral shRNA infection in dorsal CA1 region (about 30% of the dorsal CA1 region), it was quite surprising that a reduction of functional $I_h$ made such significant changes in behaviors. Furthermore, the ventral hippocampus (which corresponds to anterior hippocampus in humans) is known to be heavily involved in emotion-related behaviors such as fear and anxiety, so we assumed that we might see similar behavioral effects following a reduction of HCN1 protein expression in ventral CA1 region. However, in spite of a reduction of $I_h$ in ventral CA1 neurons from the viral shRNA infection, there were no effects on anxiolytic- or antidepressant-like behaviors. These results suggest that a reduction of functional $I_h$ in dorsal versus ventral CA1 region produced differential behavioral outputs.

The rodent hippocampus can be separated into dorsal and ventral regions based on the functional differentiation. In particular, intrinsic membrane properties of CA1 neurons between dorsal and ventral hippocampus are quite different. For example, dorsal CA1 neurons have more hyperpolarized resting membrane potential and a lower input resistance at rest compared with ventral CA1 neurons. In addition, higher resting G-protein-coupled inwardly rectifying $K^+$ channels conductance activated by A1 adenosine receptors are present in dorsal compared with ventral CA1 neurons. Because we observed antidepressant- and anxiolytic-like effects following a reduction of HCN1 protein in dorsal but not ventral CA1 region in normal rats, the important questions are (1) whether function and expression of HCN1 channels are altered during the development of depression, (2) whether changes in functional $I_h$ and HCN1 protein expression occur in dorsal or ventral or both region of hippocampus, and (3) whether a reduction of HCN1 protein expression can prevent the development of depression (i.e., resilient effects to chronic unpredictable stress (CUS)). In a recent study published in *Molecular Psychiatry*, we addressed these issues.

Chronic stress can be a risk factor for the development of depression. Depressed patients show relatively high cortisol levels due to CUS-induced impairment of hypothalamus–pituitary–adrenal axis. In this regard, CUS protocol has been widely used as an experimental tool to examine the development of psychopathology, including depression. When rats are exposed to random, intermittent, and unpredictable stress daily for two to four weeks, rats show a decreased sucrose preference (i.e., anhedonia), increased anxiety, and increased passive activity in an extremely stressful environment (i.e., behavioral despair) (Figure 1(b)), which are all core symptoms of human depression. Using the CUS model of depression, we found that functional $I_h$ and HCN1 protein expression are increased in dorsal but not ventral CA1 neurons. This is consistent with the results shown by the differential behavioral effects observed through a reduction of HCN1 protein in dorsal versus ventral CA1 region in normal rats. In addition, biochemical assays revealed that HCN2 protein expression is also increased in dorsal but not in ventral CA1 region. Therefore, upregulation of functional $I_h$ stems from increases in both HCN1 and HCN2 protein expression in dorsal but not in ventral CA1 region, and also there is a correlation in the time courses for upregulation of $I_h$ and depression-like symptoms during the development of depression. In addition, when depressed rats were not exposed to further CUS for four weeks (i.e., recovery period), an increase in passive activity (in forced swim test) and upregulation of $I_h$ were back to normal levels (Figure 1(b)).

One of the key features of HCN1 (and HCN2) channels in the hippocampus is a distant-dependent increase in channel expression along the somatodendritic axis. Given the contributions of HCN1 channels to neuronal excitability and synaptic integration, a change in subcellular expression of HCN1 channels along the somatodendritic axis of CA1 neurons has been implicated in the neuropathology of psychiatric disorders such as epilepsy. Interestingly, we found that upregulation of functional $I_h$
is limited to the perisomatic but not dendritic region of dorsal CA1 neurons in CUS model of depression (Figure 1(d)). This abnormal perisomatic upregulation of $I_h$ might be due to (1) the increases in cytoplasmic calcium levels, which in turn activate inositol 1,4,5-trisphosphate receptors and store-operated channels or (2) the involvement of specific TRIP8b isoforms (e.g., an increase in $I_h$ by isoform A4 and a decrease in $I_h$ by isoform B2).

Major depression is the most frequent psychiatric comorbidity in patients with temporal lobe epilepsy (TLE). Because treatment for patients with comorbid epilepsy and major depression is difficult due to the fact that (1) conventional antidepressant drugs can lower seizure threshold and (2) antiepileptic drugs can cause mood instability. When HCN1 protein was reduced in dorsal CA1 region, we did not observe any abnormal epileptic-like activity in voltage-sensitive dye imaging and extracellular field potential recording. Interestingly, a reduction of dendritic $I_h$ in CA1 region of hippocampus was observed in the kainic acid-induced poststatus epilepticus model of TLE. Therefore, changes in subcellular expression of functional $I_h$ might be a cellular and molecular consequences of major depression and TLE.

Major depressive disorder (MDD) is a disorder of neural circuitry in limbic–cortical areas. Functional brain imaging of major depressed patients shows increased or decreased regional metabolic activities in different regions of these areas, which can be reversed by clinical antidepressant treatment or chronic electrical stimulation. There is a strong positive correlation between brain energy metabolism and neuronal excitability. Neuronal excitability can be determined by measurements of input resistance and action potential firing of neurons at rest. Interestingly, bimodal, abnormal changes in neuronal excitability were observed in depressed patients compared to normal controls.
in regional metabolic activities in different regions of limbic–cortical areas, increased neuronal excitability of lateral amygdala neurons,19 or decreased neuronal excitability of dorsal CA1 neurons (i.e., shRNA-control and shRNA-HCN1) following chronic stress have all been reported (Figure 1(c)). In addition, functional $I_{\text{h}}$ and neuronal excitability of lentiviral-shRNA-infected dorsal CA1 neurons (i.e., shRNA-control and shRNA-HCN1) before and after development of depression. (D and E) A reduction of HCN1 protein expression leads to increases in fEPSPs, hippocampal activity, mature BDNF, and pmTOR protein expression.

AP: action potential; BDNF: brain-derived neurotrophic factor; CUS: chronic unpredictable stress; fEPSP: field excitatory postsynaptic potential; HCN: hyperpolarization-activated cyclic nucleotide-gated nonselective cation; pmTOR phosphorylation of mTOR.

Figure 2. A reduction of functional $I_{\text{h}}$ in dorsal CA1 region/neurons confers resiliency to CUS. (a) Representative illustration of development of resilience to CUS. (b and c) Changes in functional $I_{\text{h}}$ and neuronal excitability of lentiviral-shRNA-infected dorsal CA1 neurons (i.e., shRNA-control and shRNA-HCN1) before and after development of depression. (D and E) A reduction of HCN1 protein expression leads to increases in fEPSPs, hippocampal activity, mature BDNF, and pmTOR protein expression.

AP: action potential; BDNF: brain-derived neurotrophic factor; CUS: chronic unpredictable stress; fEPSP: field excitatory postsynaptic potential; HCN: hyperpolarization-activated cyclic nucleotide-gated nonselective cation; pmTOR phosphorylation of mTOR.

in regional metabolic activities in different regions of limbic–cortical areas, increased neuronal excitability of lateral amygdala neurons,19 or decreased neuronal excitability of dorsal CA1 neurons following chronic stress have all been reported (Figure 1(c)). In addition, functional $I_{\text{h}}$ and neuronal excitability of lentiviral-shRNA-infected dorsal CA1 neurons (i.e., shRNA-control and shRNA-HCN1) before and after development of depression. (D and E) A reduction of HCN1 protein expression leads to increases in fEPSPs, hippocampal activity, mature BDNF, and pmTOR protein expression.

AP: action potential; BDNF: brain-derived neurotrophic factor; CUS: chronic unpredictable stress; fEPSP: field excitatory postsynaptic potential; HCN: hyperpolarization-activated cyclic nucleotide-gated nonselective cation; pmTOR phosphorylation of mTOR.

in regional metabolic activities in different regions of limbic–cortical areas, increased neuronal excitability of lateral amygdala neurons,19 or decreased neuronal excitability of dorsal CA1 neurons following chronic stress have all been reported (Figure 1(c)). In addition, functional $I_{\text{h}}$ and neuronal excitability of lentiviral-shRNA-infected dorsal CA1 neurons (i.e., shRNA-control and shRNA-HCN1) before and after development of depression. (D and E) A reduction of HCN1 protein expression leads to increases in fEPSPs, hippocampal activity, mature BDNF, and pmTOR protein expression.

AP: action potential; BDNF: brain-derived neurotrophic factor; CUS: chronic unpredictable stress; fEPSP: field excitatory postsynaptic potential; HCN: hyperpolarization-activated cyclic nucleotide-gated nonselective cation; pmTOR phosphorylation of mTOR.
CA1 neurons in the animal model of depression might offer difficulties to carry spatial-related information to downstream brain regions. Indeed, impaired spatial learning and memory was often observed in depressed patients.\textsuperscript{25} Furthermore, forebrain-specific HCN1 knock-out mice showed enhanced short- and long-term spatial learning and memory.\textsuperscript{26} Most of the depression researches to date have been focused on finding the mechanisms underlying the action of depression and antidepressants. Recently, there is a growing interest in the concept of the “susceptibility to depression” and “resilience to depression” in stressful environments.\textsuperscript{27} Why do some people become depressed (i.e., susceptibility to depression), while others are not (i.e., resiliency to depression) following stressful life events? Resilience is considered to be a positive coping process from adverse stress. In a recent report, a single or multiple injections of neuropeptide Y (NPY) into basolateral amygdala produced resilience to stress in rats through a reduction of functional $I_h$.\textsuperscript{28} Importantly, we also found that a reduction of $I_h$ in dorsal CA1 region before the CUS-induced onset of depression is sufficient to provide resilient effects to CUS (Figure 2). Before onset of CUS-induced depression, a reduction of functional $I_h$ in dorsal CA1 region/neurons led to (1) changes in intrinsic membrane properties, (2) an increase in neuronal excitability, (3) an enhancement of the BDNF-mTOR signaling pathways, (4) an increase in field excitatory postsynaptic potentials, and (5) an increase in dorsal hippocampal activity\textsuperscript{9} (Figure 2). These cellular changes might prime the brain to prevent the development of depression (i.e., resilience to depression).

It is quite amazing that a reduction of a single ion channels (i.e., HCN1) in a certain brain region (i.e., dorsal CA1 region) can change physiological, biochemical, and behavioral outputs. However, targeting HCN1 channels might not be a viable clinical approach for major depression due to (1) the lack of a subunit-specific inhibitor of HCN channels, (2) the fact that the HCN1 channel is also expressed in the heart and thus inhibitors could have effects on cardiac function, and (3) the changes in opposing directions in different brain regions (e.g., dorsal CA1 region vs. VTA). In this regard, targeting a brain region-specific manipulation of HCN1 channels using a viral delivery system (i.e., adeno-associated virus system) might be a possible clinical approach. Alternatively, the auxiliary subunit of HCN channels, TRIP8b, could also be an important and viable target for treatment of major depression.

**Author Contributions**

C.S.K. and D.J. developed the structure and arguments for the paper and wrote the paper. C.S.K. designed and produced the figures. All authors approved the final version of the paper.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interests with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: C.S.K. received 2017 Young Investigator award (#26382) from Brain & Behavior Research Foundation. D.J. received National Institutes of Health grant (NS084473).

**ORCID iD**

Chung Sub Kim \(\text{http://orcid.org/0000-0002-2039-3476}\)

**References**